Legend Biotech

Legend Biotech Corp. is a holding company, which engages in the discovery and development of novel cell therapies for oncology and other indications. It operates through the North America and China geographical segments. The company was founded on May 27, 2015 and is headquartered in Somerset, NJ.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Legend Biotech surpasses Q2 sales targets, eyes market expansion

Legend Biotech's Q2 performance exceeded expectations with strong sales and positive study data.
The company's financial position is robust, with a healthy cash balance and plans for capacity expansion.
While facing challenges such as competitive pressures and operational optimizations, opportunities for growth exist.
Strategic initiatives focus on product quality, market expansion, and regulatory advancements for CARVYKTI.

Legend Biotech reports robust Q3 sales, eyes profitability targets

Legend Biotech's Q3 performance reflects strong sales driven by CARVYKTI, while maintaining a solid financial position with a focus on expansion.
The company faces challenges in achieving profitability targets and providing clarity on future sales projections.
Opportunities lie in pipeline advancements, collaboration partnerships, and innovative market expansion strategies.

Legend Biotech reports robust earnings, eyes expansion and regulatory milestones

Legend Biotech's strong earnings and cash balance provide stability and growth opportunities.
CARVYKTI's efficacy and convenience position it well, with plans for capacity expansion and partnerships.
Challenges include regulatory scrutiny and the need for clarity on future manufacturing scale-up.
Opportunities lie in extending manufacturing capacity, pipeline advancements, and profitability projections by 2026.

Legend Biotech reports robust Q1 performance and accelerates CAR-T expansion

Legend Biotech's Q1 2024 showcased strong performance with significant revenue growth and expansion plans to meet rising demand.
While facing challenges like sequential sales decrease and increased expenses, the company is leveraging strengths in production capacity and market diversification.
Opportunities lie in regulatory engagements for accelerated approvals, efficient market penetration strategies, and financial flexibility for future growth.
Overall, Legend Biotech's strategic focus on CAR-T therapies positions it well for continued success and innovation in the biopharmaceutical industry.

Legend Biotech excels in Q2, eyes FDA approvals and growth

Legend Biotech's Q2 2024 performance reflects strong sales growth, regulatory milestones, and promising clinical data, positioning the company for future success.
With a solid financial position, expanded production capacity, and ongoing research initiatives, Legend Biotech demonstrates resilience and strategic foresight in a competitive market landscape.
While facing challenges such as political risks and profitability targets, the company remains focused on growth opportunities and value creation for stakeholders.

Legend Biotech excels in Q3 with CARVYKTI growth and strategic advancements

Legend Biotech's Q3 performance reflects strong sales growth, regulatory milestones, and progress in clinical trials, underpinned by a robust balance sheet and strategic leadership appointments.
While challenges in outpatient treatment adoption and trial enrollment persist, the company's focus on innovation and operational excellence presents opportunities for future growth and market leadership.
Overall, Legend Biotech's solid financial standing, coupled with its expanding product portfolio and research capabilities, positions the company favorably for continued success and value creation for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that new and updated data from the CARTITUDE clinical development program evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for patients with multiple myeloma will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2024 European Hematology Association's (EHA) Hybrid Congress. Data from Cohort D of the Ph.

Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

Legend Biotech Corporation (NASDAQ:LEGN ) Q1 2024 Earnings Call Transcript May 13, 2024 8:00 AM ET Company Participants Jessie Yeung - Head of Investor Relations and Public Relations Ying Huang - Chief Executive Officer Lori Macomber - Chief Financial Officer Guowei Fang - Chief Scientific Officer and Head of Business Development Steve Gavel - Senior Vice President, Commercial Development, US and Europe Conference Call Participants Jessica Fye - J.P. Morgan Gena Wang - Barclays Kelly Shi - Jefferies Omar Saad - Evercore ISI Yaron Werber - TD Cowen Ziyi Chen - Goldman Sachs Leonid Timashev - RBC Capital Markets Vikram Purohit - Morgan Stanley Kostas Biliouris - BMO Capital Markets George Farmer - Scotiabank Justin Zelin - BTIG Ashwani Verma - UBS Sean McCutcheon - Raymond James Mitchell Kapoor - H.C.

Legend Biotech Corporation (LEGN) Q1 2024 Earnings Call Transcript

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2024 unaudited financial results and key corporate highlights. “Legend made great progress in the first quarter, culminating in our exciting announcements in recent weeks. We received label expansions for CARVYKTI in the U.S., Europe, and Brazil that have changed the treatment paradigm for multiple myeloma and will enable more patients to.

Legend Biotech Reports First Quarter 2024 Results and Recent Highlights

Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Legend Biotech (LEGN) Ahead of Earnings?

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that the European Commission (EC) has granted approval of CARVYKTI® (ciltacabtagene autoleucel, cilta-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), have demonstrated disease progression o.

CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, May 13, 2024, to review first-quarter 2024 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech's performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this weblink. A replay version of the.

Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results

Legend Biotech (LEGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Legend Biotech (LEGN) Stock Might be a Great Pick

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI), and an immunomodulatory agent (IMiD), and are refractory to lenalidomide.1 CARVYKTI.

Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today released its inaugural Environmental, Social & Governance (ESG) report. The inaugural report provides an overview of Legend Biotech's ESG program and reporting in alignment with the Sustainable Accounting Standards Board (“SASB”) Biotechnology and Pharmaceutical sector standards, the Company's ESG data collection and disclosure roadmap, and future growth areas.

Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended CARVYKTI® (ciltacabtagene autoleucel, cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IM.

CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Legend Biotech Corporation (NASDAQ:LEGN ) Q4 2023 Earnings Conference March 11, 2024 8:00 AM ET Company Participants Jessie Yeung - Head of Investor Relations and Public Relations Ying Huang - Chief Executive Officer Lori Macomber - Chief Financial Officer Guowei Fang - Chief Scientific Officer and Head of Business Development Steve Gavel - Senior Vice President, Commercial Development, US and Europe Conference Call Participants Jessica Fye - J.P. Morgan Jonathan Miller - Evercore ISI Ziyi Chen - Goldman Sachs Dave Windley - Jefferies Leonid Timashev - RBC Capital Markets Vikram Purohit - Morgan Stanley Kostas Biliouris - BMO Capital Markets Ashwani Verma - UBS Edward Tenthoff - Piper Sandler Justin Zelin - BTIG Mitchell Kapoor - H.C.

Legend Biotech Corporation (LEGN) Q4 2023 Earnings Call Transcript

The biotech industry is evolving rapidly, with 2024 poised to be a year of significant advancements and opportunities. Amidst an uncertain macroeconomic environment, the biotech sector is gaining momentum, fueled by groundbreaking innovations and favorable market conditions.

Next-gen leaders: The biotech stock set to soar on groundbreaking innovation

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its fourth quarter and full year 2023 unaudited financial results and key corporate highlights. “With worldwide sales of half a billion dollars in its first full year of commercialization, our rapid, successful launch of CARVYKTI® reinforces its position as a leading CAR-T therapy for patients with relapsed and refractory multiple myeloma,” said Ying Huang.

Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights

Ascendis Pharma

Exact Sciences

Exelixis

Morphosys AG - ADR

We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.

5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended expansion of the CARVYKTI® label to include adult patients with relapsed and refractory multiple myeloma, who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor, have demonstrated disease pr.

Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases, will host a conference call for investors at 8:00 am ET on Monday, March 11, 2024, to review fourth-quarter and full-year 2023 results. During the webcast and conference call, executive members will provide an overview of Legend Biotech's performance for the quarter and the f.

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results

Bristol-Myers

Gilead Sciences

Johnson & Johnson

Novartis

The FDA directs companies like NVS, BMY, GILD and others to add "boxed warning" to the labels of their CAR T-cell immunotherapies after it identified adverse events.

FDA Demands "Boxed Warning" to CAR T-Cell Therapy Labels

NANJING, China , Jan. 4, 2024 /PRNewswire/ -- GenScript Biotech, a global leader in life science research and manufacturing services, along with its subsidiaries GenScript ProBio and Legend Biotech, will be attending the 42nd JPM Healthcare Conference held in San Francisco, California, USA, from January 8 to 11, 2024. This initiative aims to showcase GenScript's exceptional strength and development potential in the biotech sector, seeking to establish deeper interactions and connections with industry partners and investors, explore future collaboration opportunities, and further advance innovation and development in the healthcare sector.

GenScript, GenScript ProBio, and Legend Biotech Will Attend the 42nd JPM Healthcare Conference, Advancing Innovation and Development in the Healthcare Sector

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases, closed its previously announced exclusive, worldwide license agreement with Novartis Pharma AG (Novartis) for certain Legend Biotech chimeric antigen receptor T-cell (CAR-T) cell therapies targeting Delta-like ligand protein 3 (DLL3), including Legend Biotech's existing autol.

Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases, today announced its participation in the 42nd annual J.P. Morgan Healthcare Conference in San Francisco, CA. Ying Huang, Ph.D., the company's chief executive officer, will deliver the company presentation on Tuesday, January 9, 2024, at 2:15 p.m. PT. The live audio webcast wi.

Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

NEW YORK , Dec. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Legend Biotech Corporation ("Legend" or the "Company") (NASDAQ: LEGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Legend Biotech Corporation - LEGN

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases, announced today patient-reported outcome (PRO) data from the Phase 3 CARTITUDE-4 study from an oral presentation at the 2023 American Society of Hematology (ASH) Annual Meeting (Abstract #1063). These data showed clinically meaningful improvement in health-related quality of.

Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)

The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.

CAR T-Cell Therapies Under FDA Watch on Reports of Malignancies

Legend Biotech Corporation (NASDAQ:LEGN ) Q3 2023 Earnings Conference Call November 20, 2023 8:00 AM ET Company Participants Jessie Yeung - Head of Investor Relations and Public Relations Ying Huang - Chief Executive Officer Lori Macomber - Chief Financial Officer Steve Gavel - Senior Vice President, Commercial Development, Us and Europe Guowei Fang - Chief Scientific Officer and Head of Business Development Conference Call Participants Gena Wang - Barclays Jessica Fye - JPM Chase Kelly Shi - Jefferies Vikram Purohit - Morgan Stanley Leonid Timashev - RBC Capital Markets Yaron Werber - TD Cowen Linhai Zhao - Goldman Sachs Jonathan Miller - Evercore ISI Ashwani Verma - UBS Kostas Biliouris - BMO Capital Markets Justin Zelin - BTIG Mitchell Kapoor - H.C. Wainwright Wilfred Yuen - Daiwa Kelsey Goodwin - Guggenheim Sami Corwin - William Blair Operator Good day, ladies and gentlemen.

Legend Biotech Corporation (LEGN) Q3 2023 Earnings Call Transcript

Legend Biotech Corporation (NASDAQ:LEGN) highlighted an exclusive license agreement struck with Novartis AG (ADR) (NYSE:NVS) worth up to $1.11 billion as it released third-quarter results. Under the agreement, its Legend Biotech Ireland subsidiary has granted Novartis the rights to develop, manufacture and commercialize its CAR-T cell therapy candidate LB2102 and other potential chimeric antigen receptor T-cell therapies selectively targeting Delta-like ligand 3 (DLL3).

News for Legend Biotech Stock (LEGN)